Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of BI 695501 (Cyltezo) in Rheumatoid Arthritis
NCT02640612Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Patients With Drug-related Adverse Events up to 58 weeks. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02640612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640612.